文献速递白血病造血干细胞移植与细胞治疗

一种靶向CD38的单链T细胞衔接器通过IFN-γ诱导的CD38表达靶向白血病干细胞

A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ-induced CD38 expression.
PubMed 文献 · Blood · 2024-01-01

急性髓系白血病(AML)白血病干细胞(LSC)常富集于CD34阳性CD38阴性组分且治疗抵抗。研究发现干扰素γ(IFN-γ)经干扰素调节因子1转录激活CD38启动子,诱导CD38阳性与阴性LSC富集母细胞CD38上调并降低LSC克隆活性。据此构建单链CD38-CD3 T细胞衔接器BN-CD38,在体外和体内模型中通过诱导IFN-γ释放驱动CD38阴性LSC富集母细胞CD38表达并清除白血病细胞,且不影响正常造血干细胞克隆活性。

要点

  • AML的LSC常富集于CD34阳性CD38阴性母细胞组分,是治疗抵抗和复发的重要来源。
  • IFN-γ经干扰素调节因子1转录激活CD38启动子,使CD38阳性与阴性LSC富集母细胞CD38上调。
  • BN-CD38在自体环境中激活CD4阳性与CD8阳性T细胞,诱导IFN-γ释放并清除LSC富集母细胞。

核心结论

  • BN-CD38通过诱导IFN-γ释放驱动CD34阳性CD38阴性LSC富集母细胞表达CD38并将其清除,为靶向和清除AML的LSC提供了重要思路。

研究设计与样本

  • 研究为实验室与动物模型研究,涉及AML细胞系和患者来源异种移植模型,并在CD34阳性人源化小鼠中评估对正常造血的影响。

主要发现

  • IFN-γ降低LSC克隆活性,并使CD38阳性与CD38阴性LSC富集母细胞的CD38表达上调。
  • IFN-γ诱导的CD38上调依赖干扰素调节因子1对CD38启动子的转录激活。
  • BN-CD38连接自体CD4阳性与CD8阳性T细胞及CD38阳性AML母细胞,导致T细胞活化和扩增并清除白血病细胞。
  • BN-CD38结合后诱导高水平IFN-γ释放,驱动CD34阳性CD38阴性LSC富集母细胞表达CD38并随后被清除。
  • BN-CD38在多种播散性AML细胞系和患者来源异种移植模型中显示体内疗效,且不影响正常造血干细胞克隆活性及CD34阳性人源化小鼠多系人免疫细胞发育。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment resistance of leukemia stem cells (LSCs) and suppression of the autologous immune system represent major challenges to achieve a cure in acute myeloid leukemia (AML). Although AML blasts generally retain high levels of surface CD38 (CD38pos), LSCs are frequently enriched in the CD34posCD38neg blast fraction. Here, we report that interferon gamma (IFN-γ) reduces LSCs clonogenic activity and induces CD38 upregulation in both CD38pos and CD38neg LSC-enriched blasts. IFN-γ-induced CD38 upregulation depends on interferon regulatory factor 1 transcriptional activation of the CD38 promoter. To leverage this observation, we created a novel compact, single-chain CD38-CD3 T-cell engager (BN-CD38) designed to promote an effective immunological synapse between CD38pos AML cells and both CD8pos and CD4pos T cells. We demonstrate that BN-CD38 engages autologous CD4pos and CD8pos T cells and CD38pos AML blasts, leading to T-cell activation and expansion and to the elimination of leukemia cells in an autologous setting. Importantly, BN-CD38 engagement induces the release of high levels of IFN-γ, driving the expression of CD38 on CD34posCD38neg LSC-enriched blasts and their subsequent elimination. Critically, although BN-CD38 showed significant in vivo efficacy across multiple disseminated AML cell lines and patient-derived xenograft models, it did not affect normal hematopoietic stem cell clonogenicity and the development of multilineage human immune cells in CD34pos humanized mice. Taken together, this study provides important insights to target and eliminate AML LSCs.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Murtadha M, Park M, Zhu Y, et al. A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ-induced CD38 expression. Blood. 2024. PMID: 38394668. doi:10.1182/blood.2023021570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。